|
WO2003033520A2
(en)
|
2001-09-24 |
2003-04-24 |
University Of Pittburgh Of The Commonwealth System Of Higher Education |
Anticancer vaccine and diganostic methods and reagents
|
|
ATE417065T1
(de)
|
2004-05-19 |
2008-12-15 |
Medigene Ltd |
Hochaffiner ny-eso-t-zellen-rezeptor
|
|
JP5255274B2
(ja)
|
2004-07-06 |
2013-08-07 |
スリーディー マトリックス， インコーポレイテッド |
精製両親媒性ペプチド組成物およびその使用
|
|
US7994298B2
(en)
|
2004-09-24 |
2011-08-09 |
Trustees Of Dartmouth College |
Chimeric NK receptor and methods for treating cancer
|
|
WO2007044033A2
(en)
*
|
2004-12-07 |
2007-04-19 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen
|
|
EP1699826B1
(en)
|
2005-01-05 |
2009-03-11 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
|
|
GB0511124D0
(en)
*
|
2005-06-01 |
2005-07-06 |
Avidex Ltd |
High affinity melan-a t cell receptors
|
|
IL296832A
(en)
|
2005-10-18 |
2022-11-01 |
Nat Jewish Health |
Process of preparing red blood cells using conditionally immortalized long-term hematopoietic stem cells and erythropoietin
|
|
WO2007073147A1
(en)
*
|
2005-12-20 |
2007-06-28 |
Erasmus University Medical Center Rotterdam |
Apoptosis-inducing protein complexes and therapeutic use thereof
|
|
AT503861B1
(de)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von t-zell-rezeptoren
|
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
|
US8088379B2
(en)
|
2006-09-26 |
2012-01-03 |
The United States Of America As Represented By The Department Of Health And Human Services |
Modified T cell receptors and related materials and methods
|
|
EP2087000A2
(en)
*
|
2006-09-29 |
2009-08-12 |
Immunocore Ltd. |
T cell therapies
|
|
WO2008037943A1
(en)
*
|
2006-09-29 |
2008-04-03 |
Medigene Limited |
Cells transformed with nucleic acid encoding ny-eso t cell receptors
|
|
ES2627223T3
(es)
|
2007-06-26 |
2017-07-27 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H |
Presentación de agentes de unión
|
|
CA2700278A1
(en)
*
|
2007-09-25 |
2009-04-02 |
The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services |
Modified t cell receptors and related materials and methods
|
|
EP2113255A1
(en)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Cytotoxic immunoglobulin
|
|
SG10201803982TA
(en)
|
2008-05-16 |
2018-07-30 |
Taiga Biotechnologies Inc |
Antibodies and processes for preparing the same
|
|
US8748170B2
(en)
|
2008-07-25 |
2014-06-10 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Polypeptides derived from cyclin B1 and uses thereof
|
|
DK3339321T3
(da)
|
2008-08-28 |
2021-06-21 |
Taiga Biotechnologies Inc |
Modulatorer af myc, fremgangsmåder til anvendelse af samme og fremgangsmåder til at identificere stoffer der modulerer myc
|
|
GB0816096D0
(en)
*
|
2008-09-04 |
2008-10-15 |
Medigene Ltd |
Diabetes t cell receptors
|
|
GB0908613D0
(en)
|
2009-05-20 |
2009-06-24 |
Immunocore Ltd |
T Cell Reseptors
|
|
WO2011059836A2
(en)
|
2009-10-29 |
2011-05-19 |
Trustees Of Dartmouth College |
T cell receptor-deficient t cell compositions
|
|
US12492376B2
(en)
|
2009-10-29 |
2025-12-09 |
The Trustees Of Dartmouth College |
T-cell receptor-deficient T cell compositions
|
|
US9273283B2
(en)
|
2009-10-29 |
2016-03-01 |
The Trustees Of Dartmouth College |
Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
|
|
BR112013003647A2
(pt)
*
|
2010-07-28 |
2017-11-07 |
Immunocore Ltd |
receptores de células t.
|
|
WO2013033626A2
(en)
|
2011-08-31 |
2013-03-07 |
Trustees Of Dartmouth College |
Nkp30 receptor targeted therapeutics
|
|
WO2013041865A1
(en)
*
|
2011-09-22 |
2013-03-28 |
Immunocore Limited |
T cell receptors
|
|
WO2013048243A1
(en)
|
2011-09-29 |
2013-04-04 |
Apo-T B.V. |
Multi-specific binding molecules targeting aberrant cells
|
|
CA2860914A1
(en)
|
2012-01-13 |
2013-07-18 |
Apo-T B.V. |
Aberrant cell-restricted immunoglobulins provided with a toxic moiety
|
|
WO2013169691A1
(en)
|
2012-05-07 |
2013-11-14 |
Trustees Of Dartmouth College |
Anti-b7-h6 antibody, fusion proteins, and methods of using the same
|
|
EP2852613B1
(en)
|
2012-05-22 |
2019-01-23 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Murine anti-ny-eso-1 t cell receptors
|
|
US9789135B2
(en)
|
2012-07-20 |
2017-10-17 |
Taiga Biotechnologies, Inc. |
Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
|
|
KR102499753B1
(ko)
|
2012-07-27 |
2023-02-16 |
더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 |
Ｔ 세포 수용체 조작
|
|
US10272115B2
(en)
|
2013-03-11 |
2019-04-30 |
Taiga Biotechnologies, Inc. |
Production and use of red blood cells
|
|
EP3404111A1
(en)
|
2013-03-13 |
2018-11-21 |
Health Research, Inc. |
Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen
|
|
US9937207B2
(en)
|
2013-03-21 |
2018-04-10 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell receptor genes using talens
|
|
AU2014301777B2
(en)
|
2013-06-26 |
2017-03-30 |
Xlifesc, Ltd. |
High-stability T-cell receptor and preparation method and application thereof
|
|
KR102415259B1
(ko)
|
2013-11-22 |
2022-06-30 |
더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 |
조작된 고-친화도의 인간 t 세포 수용체
|
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
|
WO2015085147A1
(en)
|
2013-12-05 |
2015-06-11 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
|
KR20230076867A
(ko)
|
2013-12-20 |
2023-05-31 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신생항원 백신과의 병용 요법
|
|
NZ724320A
(en)
*
|
2014-03-14 |
2022-05-27 |
Adaptimmune Ltd |
Tcr libraries
|
|
US10526391B2
(en)
|
2014-07-22 |
2020-01-07 |
The University Of Notre Dame Du Lac |
Molecular constructs and uses thereof
|
|
WO2016054086A1
(en)
*
|
2014-09-30 |
2016-04-07 |
The Regents Of The University Of California |
Codon-optimized lentiviral vector for stem cell reprogramming
|
|
US20170335331A1
(en)
|
2014-10-31 |
2017-11-23 |
The Trustees Of The University Of Pennsylvania |
Altering Gene Expression in CART Cells and Uses Thereof
|
|
US10975442B2
(en)
|
2014-12-19 |
2021-04-13 |
Massachusetts Institute Of Technology |
Molecular biomarkers for cancer immunotherapy
|
|
EP3234130B1
(en)
|
2014-12-19 |
2020-11-25 |
The Broad Institute, Inc. |
Methods for profiling the t-cell- receptor repertoire
|
|
GB201506642D0
(en)
*
|
2015-04-20 |
2015-06-03 |
Ucl Business Plc |
T cell receptor
|
|
IL294183B2
(en)
|
2015-05-20 |
2023-10-01 |
Dana Farber Cancer Inst Inc |
shared neoantigens
|
|
CN106279404A
(zh)
*
|
2015-05-20 |
2017-01-04 |
广州市香雪制药股份有限公司 |
一种可溶且稳定的异质二聚tcr
|
|
NL2014935B1
(en)
|
2015-06-08 |
2017-02-03 |
Applied Immune Tech Ltd |
T cell receptor like antibodies having fine specificity.
|
|
WO2016205749A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
GB2592821B
(en)
|
2015-07-31 |
2022-01-12 |
Univ Minnesota |
Modified cells and methods of therapy
|
|
GB201516272D0
(en)
*
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
|
US12241053B2
(en)
|
2015-10-09 |
2025-03-04 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
AU2016355178B9
(en)
|
2015-11-19 |
2019-05-30 |
Massachusetts Institute Of Technology |
Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
|
|
GB201522592D0
(en)
*
|
2015-12-22 |
2016-02-03 |
Immunocore Ltd |
T cell receptors
|
|
US10188749B2
(en)
|
2016-04-14 |
2019-01-29 |
Fred Hutchinson Cancer Research Center |
Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
|
|
AU2017254477A1
(en)
|
2016-04-18 |
2018-11-01 |
Jennifer G. ABELIN |
Improved HLA epitope prediction
|
|
US11827688B2
(en)
|
2016-06-02 |
2023-11-28 |
Immunocore Limited |
Dosing regimen for GP100-specific TCR—anti-CD3 SCFV fusion protein
|
|
WO2018035364A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute Inc. |
Product and methods useful for modulating and evaluating immune responses
|
|
WO2018049025A2
(en)
|
2016-09-07 |
2018-03-15 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
JP2020501508A
(ja)
|
2016-09-15 |
2020-01-23 |
クアドルセプト バイオ リミテッド |
多量体、四量体および八量体
|
|
US12499971B2
(en)
|
2016-09-28 |
2025-12-16 |
The Broad Institute, Inc. |
Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
|
|
US12447213B2
(en)
|
2016-10-07 |
2025-10-21 |
The Broad Institute, Inc. |
Modulation of novel immune checkpoint targets
|
|
CN110520530A
(zh)
|
2016-10-18 |
2019-11-29 |
明尼苏达大学董事会 |
肿瘤浸润性淋巴细胞和治疗方法
|
|
GB201617714D0
(en)
|
2016-10-19 |
2016-11-30 |
Ucl Business Plc |
T Cell receptor
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
WO2018089386A1
(en)
|
2016-11-11 |
2018-05-17 |
The Broad Institute, Inc. |
Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
|
|
CN108117596B
(zh)
*
|
2016-11-29 |
2023-08-29 |
香雪生命科学技术（广东）有限公司 |
针对ny-eso的高亲和力tcr
|
|
EP3548055A4
(en)
|
2016-12-02 |
2020-08-19 |
University of Southern California |
SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE
|
|
EP3548425B1
(en)
|
2016-12-02 |
2023-03-29 |
Taiga Biotechnologies, Inc. |
Nanoparticle formulations
|
|
CN110121336A
(zh)
|
2017-01-05 |
2019-08-13 |
弗莱德哈钦森癌症研究中心 |
改善疫苗功效的系统和方法
|
|
MX2019007963A
(es)
|
2017-01-06 |
2019-10-21 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos infiltrantes de tumor (til) con agonistas de la superfamilia de recptor de factor de necrosis tumoral (tnfrsf) y combinaciones terapeuticas de til- y agonistas de tnfrsf.
|
|
CA3049165A1
(en)
|
2017-01-06 |
2018-07-12 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
|
JP2020503883A
(ja)
*
|
2017-01-13 |
2020-02-06 |
アジェナス インコーポレイテッド |
Ｎｙ−ｅｓｏ−１に結合するｔ細胞受容体およびその使用方法
|
|
US11549149B2
(en)
|
2017-01-24 |
2023-01-10 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
|
US11965892B2
(en)
|
2017-02-12 |
2024-04-23 |
Biontech Us Inc. |
HLA-based methods and compositions and uses thereof
|
|
EP3596108A4
(en)
|
2017-03-15 |
2020-12-23 |
Pandion Operations, Inc. |
TARGETED IMMUNOTOLERANCE
|
|
ES3010117T3
(en)
|
2017-03-27 |
2025-04-01 |
Hoffmann La Roche |
Improved antigen binding receptors
|
|
US11963966B2
(en)
|
2017-03-31 |
2024-04-23 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
|
WO2018183921A1
(en)
|
2017-04-01 |
2018-10-04 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
|
US12590288B2
(en)
|
2017-04-12 |
2026-03-31 |
The Broad Institute, Inc. |
Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response
|
|
EP3610266A4
(en)
|
2017-04-12 |
2021-04-21 |
Massachusetts Eye and Ear Infirmary |
TUMOR SIGNATURE OF METASTASIS, COMPOSITIONS OF SUBSTANCES AND USES THEREOF
|
|
MX2019012398A
(es)
|
2017-04-18 |
2020-09-25 |
Broad Inst Inc |
Composiciones para detectar secreciones y metodos de uso.
|
|
EP3622092A4
(en)
|
2017-05-11 |
2021-06-23 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
|
|
WO2018213726A1
(en)
|
2017-05-18 |
2018-11-22 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
US10676516B2
(en)
|
2017-05-24 |
2020-06-09 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
WO2018232195A1
(en)
|
2017-06-14 |
2018-12-20 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
EP3645021A4
(en)
|
2017-06-30 |
2021-04-21 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
|
US12049643B2
(en)
|
2017-07-14 |
2024-07-30 |
The Broad Institute, Inc. |
Methods and compositions for modulating cytotoxic lymphocyte activity
|
|
ES2905757T3
(es)
|
2017-08-03 |
2022-04-12 |
Taiga Biotechnologies Inc |
Métodos y composiciones para el tratamiento del melanoma
|
|
US10149898B2
(en)
|
2017-08-03 |
2018-12-11 |
Taiga Biotechnologies, Inc. |
Methods and compositions for the treatment of melanoma
|
|
AU2018338318B2
(en)
|
2017-09-21 |
2022-12-22 |
Massachusetts Institute Of Technology |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
AU2018334886B2
(en)
|
2017-09-22 |
2025-06-26 |
WuXi Biologics Ireland Limited |
Novel bispecific polypeptide complexes
|
|
KR102820804B1
(ko)
|
2017-09-22 |
2025-06-16 |
우시 바이올로직스 아일랜드 리미티드 |
신규한 이중특이적 cd3/cd19 폴리펩티드 복합체
|
|
WO2019070755A1
(en)
|
2017-10-02 |
2019-04-11 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
|
|
WO2019069125A1
(en)
|
2017-10-06 |
2019-04-11 |
Oslo Universitetssykehus Hf |
CHIMERIC ANTIGEN RECEPTORS
|
|
WO2019084055A1
(en)
|
2017-10-23 |
2019-05-02 |
Massachusetts Institute Of Technology |
CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
|
|
WO2019084427A1
(en)
*
|
2017-10-27 |
2019-05-02 |
Kite Pharma, Inc. |
T-LYMPHOCYTE RECEPTOR ANTIGEN BINDING MOLECULES AND METHODS OF USE THEREOF
|
|
WO2019094955A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
|
|
EP3710039A4
(en)
|
2017-11-13 |
2021-08-04 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
|
|
EP3714041A1
(en)
|
2017-11-22 |
2020-09-30 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
|
CN109837245A
(zh)
*
|
2017-11-25 |
2019-06-04 |
深圳宾德生物技术有限公司 |
一种tcr敲除的靶向ny-eso-1的t细胞受体基因修饰t细胞及其制备方法和应用
|
|
USRE50550E1
(en)
|
2017-12-06 |
2025-08-26 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US10174092B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US20210369775A1
(en)
|
2017-12-15 |
2021-12-02 |
Iovance Biotherapeutics, Inc. |
Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
|
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
|
KR20250099256A
(ko)
|
2018-01-18 |
2025-07-01 |
프레드 허친슨 캔서 센터 |
세포 활성화 상태를 조절함으로써 생체내 면역 세포의 염증 상태의 변경
|
|
TWI822726B
(zh)
|
2018-02-26 |
2023-11-21 |
德商梅迪基因免疫治療公司 |
Ｎｙｅｓｏ ｔ細胞受體
|
|
US12331095B2
(en)
|
2018-03-14 |
2025-06-17 |
Medigene Immunotherapies Gmbh |
Inducible T cell receptors and uses thereof
|
|
CA3095757A1
(en)
|
2018-04-06 |
2019-10-10 |
The Regents Of The University Of California |
Methods of treating glioblastomas
|
|
CA3096202A1
(en)
|
2018-04-06 |
2019-10-10 |
The Regents Of The University Of California |
Methods of treating egfrviii expressing glioblastomas
|
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
|
WO2019232542A2
(en)
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
|
US12036240B2
(en)
|
2018-06-14 |
2024-07-16 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
WO2020033923A1
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antigen binding agents that bind cd277 and uses thereof
|
|
US20210324357A1
(en)
|
2018-08-20 |
2021-10-21 |
The Brigham And Women's Hospital, Inc. |
Degradation domain modifications for spatio-temporal control of rna-guided nucleases
|
|
WO2020041384A1
(en)
|
2018-08-20 |
2020-02-27 |
The Broad Institute, Inc. |
3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity
|
|
WO2020068304A2
(en)
|
2018-08-20 |
2020-04-02 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease target binding and uses thereof
|
|
WO2020049496A1
(en)
|
2018-09-05 |
2020-03-12 |
Glaxosmithkline Intellectual Property Development Limited |
T cell modification
|
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
US20210379057A1
(en)
|
2018-10-16 |
2021-12-09 |
Massachusetts Institute Of Technology |
Nutlin-3a for use in treating a mycobacterium tuberculosis infection
|
|
WO2020086647A1
(en)
|
2018-10-23 |
2020-04-30 |
Regeneron Pharmaceuticals, Inc. |
Ny-eso-1 t cell receptors and methods of use thereof
|
|
US20220170097A1
(en)
|
2018-10-29 |
2022-06-02 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
|
WO2020097395A1
(en)
|
2018-11-08 |
2020-05-14 |
The Regents Of The University Of California |
Systems and methods for targeting cancer cells
|
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
KR20240091046A
(ko)
|
2018-12-21 |
2024-06-21 |
바이오엔테크 유에스 인크. |
Hla 클래스 ii-특이적 에피토프 예측 및 cd4+ t 세포 특징화를 위한 방법 및 시스템
|
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
|
WO2020180733A1
(en)
|
2019-03-01 |
2020-09-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
US20220143087A1
(en)
|
2019-03-08 |
2022-05-12 |
Klinikum Der Universitat Munchen |
Ccr8 expressing lymphocytes for targeted tumor therapy
|
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
|
EP3942023A1
(en)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
|
CN113906140B
(zh)
*
|
2019-03-18 |
2025-01-28 |
路德维格癌症研究院 |
A2/ny-eso-1特异性t细胞受体及其用途
|
|
GB201903767D0
(en)
|
2019-03-19 |
2019-05-01 |
Quadrucept Bio Ltd |
Multimers, tetramers & octamers
|
|
GB201904328D0
(en)
*
|
2019-03-28 |
2019-05-15 |
Immunocore Ltd |
Specific binding molecules
|
|
CN113874033A
(zh)
|
2019-04-08 |
2021-12-31 |
泰加生物工艺学公司 |
用于冷冻保存免疫细胞的组合物和方法
|
|
EP3969041A4
(en)
|
2019-05-14 |
2023-05-10 |
Taiga Biotechnologies, Inc. |
COMPOSITIONS AND METHODS FOR TREATMENT OF T-CELL DEPLETION
|
|
BR112021023345A2
(pt)
|
2019-05-20 |
2022-02-01 |
Pandion Operations Inc |
Imunotolerância com alvo em madcam
|
|
US20220235340A1
(en)
|
2019-05-20 |
2022-07-28 |
The Broad Institute, Inc. |
Novel crispr-cas systems and uses thereof
|
|
US20220226464A1
(en)
|
2019-05-28 |
2022-07-21 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
|
WO2020263830A1
(en)
|
2019-06-25 |
2020-12-30 |
Gilead Sciences, Inc. |
Flt3l-fc fusion proteins and methods of use
|
|
JP7674278B2
(ja)
*
|
2019-07-03 |
2025-05-09 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗ニューヨーク食道扁平上皮がん１（ｎｙ－ｅｓｏ－１）抗原結合タンパク質およびその使用方法
|
|
CN112300268B
(zh)
*
|
2019-08-02 |
2023-02-28 |
香雪生命科学技术（广东）有限公司 |
识别ny-eso-1抗原的高亲和力t细胞受体
|
|
WO2021030182A1
(en)
|
2019-08-09 |
2021-02-18 |
A2 Biotherapeutics, Inc. |
Bifunctional single variable domain t cell receptors and uses thereof
|
|
WO2021030627A1
(en)
|
2019-08-13 |
2021-02-18 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
|
AU2020327671A1
(en)
|
2019-08-13 |
2022-03-03 |
King's College London |
Immunoresponsive cells armoured with spatiotemporally restricted activity of cytokines of the IL-1 superfamily
|
|
US12421557B2
(en)
|
2019-08-16 |
2025-09-23 |
The Broad Institute, Inc. |
Methods for predicting outcomes and treating colorectal cancer using a cell atlas
|
|
WO2021041922A1
(en)
|
2019-08-30 |
2021-03-04 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
|
US12297426B2
(en)
|
2019-10-01 |
2025-05-13 |
The Broad Institute, Inc. |
DNA damage response signature guided rational design of CRISPR-based systems and therapies
|
|
US12394502B2
(en)
|
2019-10-02 |
2025-08-19 |
The General Hospital Corporation |
Method for predicting HLA-binding peptides using protein structural features
|
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
|
US12195725B2
(en)
|
2019-10-03 |
2025-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
|
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
|
US12195723B2
(en)
|
2019-11-08 |
2025-01-14 |
The Broad Institute, Inc. |
Engineered antigen presenting cells and uses thereof
|
|
US11865168B2
(en)
|
2019-12-30 |
2024-01-09 |
Massachusetts Institute Of Technology |
Compositions and methods for treating bacterial infections
|
|
US12165747B2
(en)
|
2020-01-23 |
2024-12-10 |
The Broad Institute, Inc. |
Molecular spatial mapping of metastatic tumor microenvironment
|
|
TWI890283B
(zh)
|
2020-02-14 |
2025-07-11 |
美商基利科學股份有限公司 |
結合ccr8之抗體及融合蛋白及其用途
|
|
EP4107187A4
(en)
|
2020-02-21 |
2024-07-03 |
Pandion Operations, Inc. |
TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
|
|
WO2021190980A1
(en)
|
2020-03-22 |
2021-09-30 |
Quadrucept Bio Limited |
Multimers for viral strain evolution
|
|
PH12022500012A1
(en)
|
2020-03-30 |
2023-04-03 |
Daiichi Sankyo Co Ltd |
Bispecific antibody
|
|
CN111690051B
(zh)
*
|
2020-06-28 |
2021-08-17 |
英威福赛生物技术有限公司 |
靶向ny-eso-1(157-165)表位的特异性t细胞受体及抗肿瘤应用
|
|
TW202406932A
(zh)
|
2020-10-22 |
2024-02-16 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
KR20230112632A
(ko)
|
2020-10-23 |
2023-07-27 |
애셔 바이오테라퓨틱스, 인크. |
면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
|
|
WO2022170509A1
(zh)
|
2021-02-09 |
2022-08-18 |
深圳普瑞金生物药业有限公司 |
一种tcr及其应用
|
|
TW202246511A
(zh)
|
2021-02-25 |
2022-12-01 |
美商萊爾免疫藥物股份有限公司 |
靶向ny-eso-1之增強免疫細胞療法
|
|
WO2022187280A1
(en)
|
2021-03-01 |
2022-09-09 |
Dana-Farber Cancer Institute, Inc. |
Personalized redirection and reprogramming of t cells for precise targeting of tumors
|
|
WO2022184659A1
(en)
|
2021-03-01 |
2022-09-09 |
Quadrucept Bio Limited |
Antibody domains & multimers
|
|
WO2022245671A1
(en)
|
2021-05-18 |
2022-11-24 |
Gilead Sciences, Inc. |
Methods of using flt3l-fc fusion proteins
|
|
JP2024525727A
(ja)
|
2021-07-14 |
2024-07-12 |
２セブンティ バイオ インコーポレイテッド |
抗体由来の結合ドメインに融合した操作されたｔ細胞受容体
|
|
US20250295693A1
(en)
|
2021-08-18 |
2025-09-25 |
Julius-Maximilians-Universität Würzburg |
Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs)
|
|
WO2023077028A1
(en)
|
2021-10-28 |
2023-05-04 |
Lyell Immunopharma, Inc. |
Enhanced t cell therapy targeting ny-eso-1
|
|
AU2022375782B2
(en)
|
2021-10-28 |
2026-02-26 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
JP7787991B2
(ja)
|
2021-10-29 |
2025-12-17 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｃｄ７３化合物
|
|
KR20240123836A
(ko)
|
2021-12-22 |
2024-08-14 |
길리애드 사이언시즈, 인코포레이티드 |
이카로스 아연 핑거 패밀리 분해제 및 이의 용도
|
|
US12122764B2
(en)
|
2021-12-22 |
2024-10-22 |
Gilead Sciences, Inc. |
IKAROS zinc finger family degraders and uses thereof
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
US12103971B2
(en)
|
2022-02-20 |
2024-10-01 |
Immunocore Limited |
HIV specific binding molecules
|
|
WO2023178181A1
(en)
|
2022-03-17 |
2023-09-21 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
CA3255500A1
(en)
|
2022-04-08 |
2023-10-12 |
Regeneron Pharmaceuticals, Inc. |
MULTI-PART RECEIVERS AND SIGNALING COMPLEXES
|
|
CR20240451A
(es)
|
2022-04-21 |
2024-12-04 |
Gilead Sciences Inc |
Compuestos de modulación de kras g12d
|
|
WO2023215183A1
(en)
*
|
2022-05-02 |
2023-11-09 |
Tscan Therapeutics, Inc. |
Multiplexed t cell receptor compositions, combination therapies, and uses thereof
|
|
KR20250028371A
(ko)
|
2022-07-01 |
2025-02-28 |
길리애드 사이언시즈, 인코포레이티드 |
Cd73 화합물
|
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
WO2024123794A2
(en)
*
|
2022-12-05 |
2024-06-13 |
Board Of Regents, The University Of Texas System |
A t cell receptor recognizing a her2 mutation presented on hla-a*02:01 and methods of use
|
|
WO2024124044A1
(en)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
|
|
CN116239700B
(zh)
*
|
2022-12-20 |
2024-06-21 |
浙江大学 |
一种肿瘤双靶向的三特异性t细胞衔接器及其应用
|
|
AU2023409398A1
(en)
|
2022-12-22 |
2025-06-05 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
CN116284448B
(zh)
*
|
2023-02-14 |
2024-06-21 |
浙江大学 |
一种超抗原参与的三功能t细胞衔接器及其应用
|
|
WO2024192141A1
(en)
|
2023-03-13 |
2024-09-19 |
Dana-Farber Cancer Institute, Inc. |
Treatment of cancers having a drug-resistant mesenchymal cell state
|
|
AU2024252725A1
(en)
|
2023-04-11 |
2025-11-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
CR20250446A
(es)
|
2023-04-21 |
2025-12-02 |
Gilead Sciences Inc |
Inhibidores de prmt5 y usos de los mismos
|
|
WO2024226838A2
(en)
|
2023-04-25 |
2024-10-31 |
The Brigham And Women's Hospital, Inc. |
Treatment of autoimmune diseases having a pathogenic t cell state
|
|
AU2024306338A1
(en)
|
2023-06-30 |
2026-01-08 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
CN121620513A
(zh)
|
2023-07-26 |
2026-03-06 |
吉利德科学公司 |
Parp7抑制剂
|
|
KR20260046403A
(ko)
|
2023-07-26 |
2026-04-07 |
길리애드 사이언시즈, 인코포레이티드 |
Parp7 저해제
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250101042A1
(en)
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025059533A1
(en)
|
2023-09-13 |
2025-03-20 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025117544A1
(en)
|
2023-11-29 |
2025-06-05 |
The Broad Institute, Inc. |
Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20260098049A1
(en)
|
2024-08-12 |
2026-04-09 |
Gilead Sciences, Inc. |
Kras modulating compounds
|